Aurinia Pharmaceuticals Inc.
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $283.1M
- Net income
- $287.2M
- Total assets
- $751.6M
- Market cap
- $2.0B
- Gross margin
- 88.5%
- Operating margin
- 37.1%
- Net margin
- 101.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $283.1M
- Cost of revenue
- $32.7M
- Gross profit
- $250.4M
- Operating expenses
- $178.1M
- Operating income
- $104.9M
- Income tax
- -$173.0M
- Net income
- $287.2M
- EPS (basic)
- $2.14
- EPS (diluted)
- $2.07
Balance sheet
- Total assets
- $751.6M
- Current assets
- $492.0M
- Total liabilities
- $170.3M
- Current liabilities
- $93.7M
- Shareholders’ equity
- $581.3M
Cash flow
- Operating cash flow
- $135.7M
- Investing cash flow
- -$32.8M
- Financing cash flow
- -$106.1M
- Net cash flow
- -$3.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $2.0B
- P/E ratio
- 7.6
- EPS (diluted)
- $2.07
- Shares outstanding
- 130.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 21, 2009
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $287.2M in FY2025.
- Revenue grew 465% from FY2020 to FY2025.
- Gross margin of 88.5%, net margin 101.5%.
- Trading 5% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 7.6.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Aurinia Pharmaceuticals Inc..
Write a review
News about Aurinia Pharmaceuticals Inc.
News & sentiment via Polygon.io
